MEDPACTO
MedPacto is a genome-based drug discovery and clinical-stage biotechnology company that is pursuing the development of first-in-class therapies to bring new hope to patients suffering from the most challenging diseases such as cancer. Vactosertib, an orally bioavailable small-molecule inhibitor of the TGF-type I receptor (TRI) that is currently in phase II clinical trials with global pharmaceutical companies such as Merck and AstraZeneca, is the leading drug candidate.
MEDPACTO
Social Links:
Industry:
Biotechnology Pharmaceutical
Founded:
2013-06-19
Address:
Seocho, Seoul-t'ukpyolsi, South Korea
Country:
South Korea
Website Url:
http://www.medpacto.com
Total Employee:
51+
Status:
Active
Contact:
+82 2 6938 0200
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Korea Telecom Cafe24 DNS SK Broadband
Similar Organizations
Geno Biotech
Geno Biotech is a pioneer in the field of precision medicine and is the first biotech company
Magpie Pharmaceuticals
Magpie Pharmaceuticals is a biotechnology company.
Current Employees Featured
Stock Details
Key Employee Changes
| Date | New article |
|---|---|
| 2022-03-24 | MedPacto Hires Global Clinical Expert Timothy R. Allen as Executive Vice President |
Official Site Inspections
http://www.medpacto.com Semrush global rank: 3.92 M Semrush visits lastest month: 3.23 K
- Host name: 183.111.138.201
- IP address: 183.111.138.201
- Location: South Korea
- Latitude: 37.5112
- Longitude: 126.9741
- Timezone: Asia/Seoul
More informations about "MedPacto"
MedPacto
MedPacto receives IND approval from the Ministry of Food and Drug Safety to evaluate the safety and efficacy of Vactosertib as a single agent in patients with osteosarcoma. Feb 16, 2023See details»
MedPacto
MedPacto is an innovative drug discovery and development company based in South Korea that develops therapeutics targeting cancer and autoimmune diseases. Our expertise lies in …See details»
MedPacto - Crunchbase Company Profile & Funding
MedPacto is a genome-based drug discovery and clinical-stage biotechnology company that is pursuing the development of first-in-class therapies to bring new hope to patients suffering from the most challenging diseases such as cancer.See details»
MedPacto - LinkedIn
MedPacto is a genome-based drug discovery and clinical-stage biotechnology company that is pursuing the development of first-in-class therapies to bring new hope to patients suffering …See details»
MedPacto
MedPacto is leading combination trials in collaboration with world-renowned institutions and global pharmaceutical companies such as Merck and AstraZeneca.See details»
MedPacto - businessabc.net
Nov 10, 2024 · MedPacto was founded in 2012 by a range of scientists and clinical experts in cancer and translational medicine. Early discoveries have translated into preclinical and …See details»
MedPacto Company Profile 2024: Stock Performance
MedPacto Inc is a drug discovery and development company based in South Korea. It is engaged in developing anticancer drugs and medicines which focuses on therapeutics targeting cancer and autoimmune diseases.See details»
Company MedPacto, Inc. - MarketScreener.com
Nov 14, 2024 · MedPacto, Inc. is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company researches and develops anticancer …See details»
MedPacto - Overview, News & Similar companies | ZoomInfo.com
Nov 8, 2023 · MedPacto contact info: Phone number: +82 269380200 Website: www.medpacto.com What does MedPacto do? MedPacto is a genome-based drug discovery …See details»
MedPacto
To contribute to the lives of patients and families by developing innovative and personalized therapies that target cancer and autoimmune diseases. MedPacto's steps forward for success …See details»
MedPacto - VentureRadar
MedPacto is an innovative drug discovery and development company based in South Korea that develops therapeutics targeting cancer and autoimmune diseases. Our expertise lies in …See details»
MedPacto - Products, Competitors, Financials, Employees, …
MedPacto is a drug discovery and development company that develops therapeutics targeting cancer and autoimmune diseases. Use the CB Insights Platform to explore MedPacto's full …See details»
Chime Biologics and Korean Listed Company MedPacto Form …
Oct 28, 2024 · MedPacto, known for its focus on cancer therapeutics, will leverage Chime Biologics' expertise in biologics development to streamline the process from tech transfer to …See details»
Chime Biologics and Korean Listed Company MedPacto Form
Nov 1, 2024 · MedPacto, known for its focus on cancer therapeutics, will leverage Chime Biologics’ expertise in biologics development to streamline the process from tech transfer to …See details»
MedPacto
Dr. Hyun Bae, MD is a distinguished spine fellowship and trained board-certified orthopedic surgeon practicing at Spine-center at Cedars-Sinai Medical Center and the Spine Institute in …See details»
Vactosertib by MedPacto for Refractory Multiple Myeloma: …
Sep 9, 2024 · MedPacto, a subsidiary of Theragen Etex Co Ltd, is a biotechnology company that discovers and develops therapies to treat cancer and autoimmune diseases. Its product …See details»
Chime Biologics and Korean Listed Company MedPacto Form …
Oct 28, 2024 · MedPacto (KOSDAQ: 235980) is a South Korean biomarker-driven drug discovery and development company specializing in innovative therapies for cancer. Through …See details»
MedPacto
MedPacto’s anticancer assets are developed to treat based on biomarker expression, which is agnostic to any specific tumor tissue type, and to combine with various therapeutic options. …See details»
Chime Biologics and MedPacto Form Strategic Partnership to …
Oct 29, 2024 · MedPacto, known for its focus on cancer therapeutics, will leverage Chime Biologics' expertise in biologics development to streamline the process from tech transfer to …See details»
MedPacto
Field of cancer treatment is focused on combining a tumor-targeting anticancer agent and a drug that modulates the tumor microenvironment.See details»